Jeffrey Lawrence Appointed Chairman of Joe & the Juice
24.4.2025 09:00:00 CEST | Business Wire | Press Release
Joe & the Juice (“the Company”), an urban juice bar and coffee concept selling freshly prepared juices, coffee, sandwiches and more, today announced that Jeffrey Lawrence, a member of the Company’s Board of Directors since April 2024, has been appointed as Chairman of the Board.
Thomas Nørøxe, Chief Executive Officer of Joe & the Juice, said, “Jeff’s elevation to Chairman of Joe & the Juice reflects how his active participation has made a material difference to the Company’s performance and strategy. Over the past year, Joe & the Juice has achieved continued impressive same store sales and revenue growth as we also opened our 400th unit globally. Unit economics remain incredibly strong and digital sales are now nearing 40%. Jeff’s experience will be vital as we continue to expand globally through both company-owned and franchise openings.”
Jeffrey Lawrence commented, “Joe & the Juice continues to represent one of the most exciting and dynamic restaurant brands, with true global consumer appeal. Over time, the Company has finetuned a winning formula to provide fresh, quality products, with a focus on hospitality and meeting the needs of today’s digitally-enabled consumer. I have been inspired by the ambition and potential of the team and look forward to working closely together to continue to build the Joe & the Juice brand globally.”
Mr. Lawrence holds more than 25 years of leadership experience in building digitally-enabled foodservice and consumer brands. He spent more than two decades at Domino’s Pizza (NYSE: DPZ), including five years as Executive Vice President and Chief Financial Officer, playing a critical role in the company’s successful IPO, its significant international expansion and best in class increases in store-level profitability. Mr. Lawrence was also an integral part of the global pizza chain’s transformation through the adoption and optimization of digital and data-led initiatives.
After his time at Domino’s, Mr. Lawrence served as CFO of FIGS, Inc. (NYSE: FIGS), a direct-to-consumer apparel brand, where he led the company’s 2021 IPO, and then as CFO at ShiftKey.
He currently serves as an independent board member and Chairman of the Audit Committee at Shake Shack (NYSE: SHAK) and an independent board member at Xponential Fitness (NYSE: XPOF), as well as a Senior Advisor to General Atlantic, a leading global growth investor.
Joe & the Juice currently operates in more than 400 locations across 19 countries spanning the UK and Europe, United States, Middle East and Asia. Capitalizing on strong customer demand, the Company’s enhanced digital distribution channels and strong franchising partnerships have enabled it to rapidly expand its regional presence in key markets.
About Joe & the Juice
Joe & the Juice is an urban juice bar and coffee concept operating in more than 400 locations across 19 countries. Founded in 2002, the company sells freshly prepared juices, coffee, sandwiches and more. Joe & the Juice’s differentiated concept creates a modern, urban, and hip ambiance for on-the-go customers focused on a healthy lifestyle. For more on our authentic and unique brand: www.joejuice.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424086704/en/
Contacts
Media Contacts
Joe & the Juice
Kasper Garnell
garnell@joejuice.com
+45 2019 5904
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom